Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 13 Mar 2025 |
| Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) | 12 Mar 2025 |
| Orion Corporation: Managers' transactions - Hao Pan | 11 Mar 2025 |
| Orion Corporation: Managers' transactions - Outi Vaarala | 11 Mar 2025 |
| Orion Corporation: Managers' transactions - Satu Ahomäki | 11 Mar 2025 |
| Orion Corporation: Managers' transactions - René Lindell | 11 Mar 2025 |